Drugs / TRK-001
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06552169 | Jun 2025 → Dec 2027 expected | — | Singulera Therapeutics Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TRK-001 | “administering expanded regulatory T cells (TRK-001) to prevent allograft rejection in living donor renal transplant recipients.” NCT06552169 ↗ |
| Modality | Cell therapy | “autologous expanded regulatory T cells (TRK-001)” NCT06552169 ↗ |
| Route | Intravenous | “single intravenous infusion of autologous, expanded Tregs (TRK-001)” NCT06552169 ↗ |